OncoMethylome Inks Companion Dx Deals, Reports 17 Percent Revenue Drop in H1 2009

In reporting its half-year 2009 financial results last month, OncoMethylome Sciences disclosed that it has inked new partnerships with pharmaceutical companies to discover cancer biomarkers for companion diagnostic development, and is providing companion diagnostic testing services for two clinical trials on personalizing glioblastoma treatments.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories